Clinical Trials Logo

Cerebellar Ataxia clinical trials

View clinical trials related to Cerebellar Ataxia.

Filter by:

NCT ID: NCT05557786 Recruiting - Clinical trials for Spinocerebellar Ataxia Type 3

Treatment of Transcranial Alternating Current Stimulation(tACS)on Cerebellar Ataxia

Start date: August 1, 2022
Phase:
Study type: Observational

This is a longitudinal, triple-blind, randomized-controlled, prospective observational study assessing patients with cerebellar ataxia, including spinocerebellar ataxia type 3 (SCA3) and multiple system atrophy-cerebellar type (MSA-C), to examine the efficacy, safety, and tolerability of transcranial alternating current stimulation (tACS) for up to 3 months.

NCT ID: NCT05515536 Enrolling by invitation - Friedreich Ataxia Clinical Trials

A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia

Start date: December 8, 2022
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to assess the long-term safety of vatiquinone in participants with Friedreich ataxia (FA) previously exposed to vatiquinone.

NCT ID: NCT05490563 Terminated - Clinical trials for Spinocerebellar Ataxia Type 3

STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia

STRIDES
Start date: June 3, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Phase 2b/3 double blind, randomized, placebo-controlled trial to assess safety and efficacy of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of adults with spinocerebellar ataxia).

NCT ID: NCT05485987 Active, not recruiting - Friedreich Ataxia Clinical Trials

A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia

Start date: October 13, 2022
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to assess the pharmacokinetics (PK) and safety of vatiquinone administered in participants with Friedreich ataxia (FA) younger than 7 years.

NCT ID: NCT05479656 Completed - Clinical trials for Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay

A Rehabilitation Program to Increase Balance and Mobility in Ataxia of Charlevoix-Saguenay

Start date: May 13, 2019
Phase: N/A
Study type: Interventional

This exploratory study used a pre-post test design. The supervised rehabilitation program was performed three times a week for 8 weeks (two sessions at a rehabilitation gym and one pool session). Outcome measures included Ottawa sitting scale, 30-Second Chair Stand test, Berg Balance Scale, 10-Meter Walk Test, 6-minute Walk Test, modified Activities-specific Balance Confidence Scale and SARA scale. 10 participants will complete the training program. They will be evaluated at baseline, at week 4 (miway) and after the program.

NCT ID: NCT05471310 Completed - Clinical trials for Ataxia Telangiectasia

Videoocular Assessment of Eye Movement Activity in an Ataxia Telangiectasia

Start date: March 15, 2021
Phase:
Study type: Observational

Ataxia-telangiectasia (A-T) is a multisystem auto-somal recessive disorder linked to the A-T mutated gene (ATM) on chromosome 11q22-23, and characterized by progressive neural degeneration, immunodeficiency, and progressive ocular motor dysfunction. In previous studies, the quantitative description of the ocular motor deficits from clinical examination was limited to various defects in saccade and gaze control, dysmetric saccades, impairments of smooth pursuit, gaze holding, convergence, vestibular and optokinetic nystagmus slow phases, and cancellation of the vestibulo-ocular reflex. The aim of our research is to add existing findings with quantitative description of oculomotor patterns in A-T patients using videooculography (VOG).

NCT ID: NCT05445323 Recruiting - Friedreich Ataxia Clinical Trials

Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia

Start date: August 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, dose-ascending, multicenter study of the safety and efficacy of LX2006 for participants who have Friedreich's Ataxia with evidence of cardiomyopathy. The study will evaluate up to three doses of single administration of LX2006 (AAVrh.10hFXN), an adeno-associated virus (AAV) gene therapy designed to intravenously deliver the human frataxin (hFXN) gene to cardiac cells over a 52-week period. Long-term safety and efficacy will be evaluated for an additional 4-years for a total of 5-years post LX2006 treatment.

NCT ID: NCT05443906 Recruiting - Clinical trials for Neurodegenerative Diseases

Home Exercise for Individuals With Neurodegenerative Disease

Start date: February 13, 2023
Phase: N/A
Study type: Interventional

The primary goal of this study is to address the need for targeted therapeutic interventions for impairments that impact walking in related neurodegenerative diseases.

NCT ID: NCT05436262 Completed - Cerebellar Ataxia Clinical Trials

Using Real-time fMRI Neurofeedback and Motor Imagery to Enhance Motor Timing and Precision in Cerebellar Ataxia

Start date: March 14, 2023
Phase: N/A
Study type: Interventional

The aim of the research is to improve motor function in people with cerebellar ataxia by using neuroimaging methods and mental imagery to "exercise" motor networks in the brain. The relevance of this research to public health is that results have the potential to reduce motor deficits associated with cerebellar atrophy, thereby enhancing the quality of life and promoting independence.

NCT ID: NCT05436249 Completed - Healthy Clinical Trials

Use of Real-Time Functional Magnetic Resonance Imaging Neurofeedback to Improve Motor Function in Cerebellar Ataxia

fMRI
Start date: December 7, 2022
Phase: N/A
Study type: Interventional

This project will study the feasibility of motor rehabilitation in people with cerebellar ataxia using real-time functional magnetic resonance imaging neurofeedback (rt-fMRI NF) in conjunction with motor imagery. To do so, data will be collected from healthy adults in this protocol, to be compared with data from cerebellar ataxia participants.